Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparing Immunohistochemical and Molecular Breast Cancer Subtyping in African Populations

  • By

  • Shahin Sayed

  • Li Feng

  • Hela Koka

  • Manel Haj Mansour

  • Difei Wang

  • Maria Brown

  • Kristine Jones

  • Margaret Maina

  • Veronica Ngundo

  • Alfred Mburu Githuka

  • Zaitun Ajuoga

  • Shaoqi Fan

  • Amber N. Hurson

  • Xing Hua

  • Petra Lenz

  • Rosemary Wangari Kamau

  • Beryl Akinyi Ooro

  • Francis Makokha

  • Stefan Ambs

  • Aaron M. Rozeboom

  • Amy Hutchinson

  • Belynda Hicks

  • Mustapha Abubakar

  • Xiaohong R. Yang

  • October 12, 2026

Share

  • 1

    Breast cancer mortality is disproportionately high in sub-Saharan Africa, where diagnostic delays, limited treatment access, and inadequate health care infrastructure contribute to poor outcomes.

  • 2

    PAM50 classifies breast tumors into 5 intrinsic subtypes but is costly and technically complex, so clinical practice often relies on IHC markers and histologic grade as surrogates.

  • 3

    The study assessed agreement between IHC-based subtyping and PAM50 in 460 Kenyan patients and validated its findings in an independent cohort of 451 Ghanaian patients.

  • 4

    PAM50 served as the reference standard, and agreement was evaluated using sensitivity, specificity, and Cohen κ statistics.

  • 5

    The study also examined duplicate-assay concordance in 44 patients and assessed agreement between Ki-67 protein and MKI67 gene expression using ROC analyses.

Original Source(s)

Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations

  • by Shahin Sayed, Li Feng, Hela Koka, Manel Haj Mansour, Difei Wang, Maria Brown, Kristine Jones, Margaret Maina, Veronica Ngundo, Alfred Mburu Githuka, Zaitun Ajuoga, Shaoqi Fan, Amber N. Hurson, Xing Hua, Petra Lenz, Rosemary Wangari Kamau, Beryl Akinyi Ooro, Francis Makokha, Stefan Ambs, Aaron M. Rozeboom, Amy Hutchinson, Belynda Hicks, Mustapha Abubakar, Xiaohong R. Yang

  • October 12, 2026

Related Content

Retraction Note: Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients’ survival by downregulating miR-21

Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors: A Secondary